AI assistant
AMGEN INC — Director's Dealing 2025
Feb 14, 2025
29819_dirs_2025-02-13_d93745fd-85cb-48dd-97af-aa6f9c7d6166.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2025-02-11
Reporting Person: Gordon Murdo (EVP, Global Commercial Ops)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-11 | Common Stock | S | 8771 | $294.7947 | Disposed | 44186 | Direct |
Footnotes
F1: The price reported is an average price. The prices ranged from $294.6101 to $294.885 per share. Full information regarding the number of shares purchased at each separate price within the range set forth is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F2: These shares include 773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.